Protease Inhibitors: all 1,856 studies that test it
Page 16 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AMLCompletedNCT00780598Phase 2
- VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1
- ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation TrialCompletedNCT00772902Phase 4
- An Evaluation of the Pharmacological Interaction of Lopinavir/r and RifampinCompletedNCT00771498Phase 4
- A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)CompletedNCT00770159Phase 1
- To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of AvanafilCompletedNCT00770042Phase 1
- Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)CompletedNCT00769418Phase 1
- TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.CompletedNCT00767117Phase 1
- The Effect of Pregnancy on the Pharmacokinetics of the Kaletra TabletCompletedNCT00766818Phase 1
- Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected SubjectsCompletedNCT00765271Phase 1
- NNRTI/PI Toxicity Switch to Darunavir StudyTerminatedNCT00765154Phase 4
- A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.CompletedNCT00765115Phase 1
- Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid MetabolismStatus unknownNCT00759070Phase 4
- TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend CapsuleCompletedNCT00752648Phase 1
- TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male VolunteersCompletedNCT00752544Phase 1
- TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir TabletCompletedNCT00752310Phase 1
- Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected PatientsCompletedNCT00752037Phase 4
- Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current TreatmentStatus unknownNCT00751153Phase 4
- TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.CompletedNCT00744887Phase 1
- Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedNCT00743795Phase 2
- A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult SubjectsTerminatedNCT00743470Phase 1
- TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.CompletedNCT00741169Phase 1
- Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's DiseaseTerminatedNCT00739037Phase 1
- A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory TumoursCompletedNCT00737555Phase 1
- Drug Interaction Study With a Potential Alzheimer's Disease CompoundCompletedNCT00726726Phase 1
- A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2
- Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk FactorsCompletedNCT00720590Not applicable
- Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAARTCompletedNCT00719602Early Phase 1
- Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy VolunteersCompletedNCT00711776Phase 1
- Nelfinavir, a Phase I/Phase II Rectal Cancer StudyCompletedNCT00704600Phase 1/2
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug CombinationsCompletedNCT00697892Phase 1
- Study With Nelfinavir and Combined Radiochemotherapy for GlioblastomaCompletedNCT00694837Phase 1
- A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)WithdrawnNCT00692458Phase 3
- Safety Study to Evaluate CHR-2797 in Patients With Advanced TumoursCompletedNCT00692354Phase 1
- A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)WithdrawnNCT00691899Phase 3
- Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes MellitusCompletedNCT00690638Phase 3
- Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)CompletedNCT00689000Phase 1/2
- Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsCompletedNCT00684710Phase 1
- Bowman-Birk Inhibitor Concentrate in Healthy MenCompletedNCT00679094Phase 1
- Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip ReplacementCompletedNCT00668031Phase 3
- Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)CompletedNCT00665951Phase 1
- A Study of the Safety of PAZ-417 in Healthy Elderly AdultsTerminatedNCT00663065Phase 1
- Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV PatientsTerminatedNCT00661349Phase 4
- TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.CompletedNCT00650832Phase 2
- Safety and Efficacy of Kaletra in ARV Therapy Experienced PatientsCompletedNCT00648999Phase 4
- Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate HypertensionStatus unknownNCT00644475Phase 3
- Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by BreastfeedingCompletedNCT00640263Phase 3
- External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesStatus unknownNCT00637637Phase 2
- Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based RegimensCompletedNCT00627055Phase 4
- Lopinavir/Ritonavir Monotherapy in ChildrenCompletedNCT00626301Phase 4
- Pharmacokinetics of Low Dose RitonavirCompletedNCT00622206Phase 1/2
- Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant WomenCompletedNCT00621166Phase 2
- Effect of PF-00734200 in Subjects With Type 2 DiabetesCompletedNCT00618007Phase 2
- Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast CancerCompletedNCT00615940Phase 2
- Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification StrategyCompletedNCT00611039Phase 4
- Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 HoursCompletedNCT00607958Phase 4
- Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During PregnancyCompletedNCT00605098Phase 4
- A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney FunctionCompletedNCT00596518Phase 1
- Moexipril for Primary Biliary CirrhosisCompletedNCT00588302Phase 2
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory SyndromeStatus unknownNCT00578825Not applicable
- MK0752 in Treating Young Patients With Recurrent or Refractory CNS CancerTerminatedNCT00572182Phase 1
- Raltegravir Kaletra PharmacokineticsCompletedNCT00564772Phase 4
- Comparison of Epzicom and Truvada for the Initial Once Daily HIV TreatmentCompletedNCT00544128Phase 4
- The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive SubjectsCompletedNCT00540137Phase 4
- Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes MellitusCompletedNCT00532506Phase 2
- Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/MclCompletedNCT00532168Phase 4
- A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.CompletedNCT00532090Phase 1
- HIV - Monotherapy in Switzerland (MOST-ch)TerminatedNCT00531986Phase 4
- Double Protease Inhibitor to Darunavir Switch StudyCompletedNCT00531557Phase 4
- Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaCompletedNCT00528060Phase 2
- HIV Antiretroviral Drugs and MetabolismStatus unknownNCT00525239Not applicable
- Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT00522938Phase 1/2
- DDI HV (ATV - Merck)CompletedNCT00518297Phase 1
- TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) PreviouslyTerminatedNCT00513513Phase 2
- Study of Telaprevir in Subjects With Hepatic ImpairmentCompletedNCT00509210Phase 1
- Kaletra Monotherapy in HIV/HCV Co-infected SubjectsCompletedNCT00508222Phase 3
- A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.CompletedNCT00502710Phase 2
- Talabostat in Treating Patients With Metastatic Kidney CancerWithdrawnNCT00489710Phase 2
- A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes MellitusStatus unknownNCT00482950Phase 2
- Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.CompletedNCT00481182Phase 1
- Study Evaluating GSI-953 in Healthy Young and Alzheimer's PatientsCompletedNCT00479219Phase 1
- Efficacy and Safety of SQV in Patients Who Have Chronic IDV NephrotoxicityCompletedNCT00477048Phase 2
- Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mgWithdrawnNCT00476983Phase 2/3
- 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With MetforminCompletedNCT00473525Phase 2
- Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant VirusesCompletedNCT00460382Phase 2
- Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) PatientsCompletedNCT00455767Phase 2
- Effect of Atazanavir on Endothelial Function in HIV-Infected PatientsCompletedNCT00447070Phase 4
- Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953CompletedNCT00441987Phase 1
- Lopinavir Capsules to Kaletra or Invirase TabletsCompletedNCT00438152Phase 4
- SHARE: Simple HAART With Abacavir, Reyataz, and EpivirStatus unknownNCT00426296Phase 4
- Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 PrimevaCompletedNCT00424814Phase 2/3
- Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136CompletedNCT00421551Phase 3
- Pharmacokinetic Study of Two HIV Protease Inhibitors in PatientsTerminatedNCT00420355Phase 4
- The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving RifampicinCompletedNCT00411996Phase 1/2
- Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected PatientsCompletedNCT00411957Phase 1/2
- Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And AtorvastatinCompletedNCT00411190Phase 1
- The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected PatientsCompletedNCT00400738Phase 2
- A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)TerminatedNCT00397683Phase 2
- Bioequivalence Study of Atazanavir 300 mg CapsuleCompletedNCT00393328Phase 1
- BASIC: Boosted Atazanavir or Saquinavir Induced Lipid ChangesCompletedNCT00389402Phase 4